Provided by Tiger Trade Technology Pte. Ltd.

Alpha Tau Medical

14.92
+0.56003.90%
Post-market: 14.950.0300+0.20%19:48 EDT
Volume:626.16K
Turnover:9.28M
Market Cap:1.38B
PE:-14.19
High:15.02
Open:14.57
Low:14.40
Close:14.36
52wk High:15.02
52wk Low:3.06
Shares:92.33M
Float Shares:63.79M
Volume Ratio:1.47
T/O Rate:0.98%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.0517
EPS(LYR):-0.5300
ROE:-141.68%
ROA:-25.71%
PB:31.27
PE(LYR):-28.15

Loading ...

Alpha Tau treats first patient in ADMIRE study for recurrent skin cancer

TIPRANKS
·
Jul 15

Alpha Tau Issues Press Release on Admire Study in Recurrent Cscc Patients

Reuters
·
Jul 15

Barclays Sticks to Its Buy Rating for Alpha Tau Medical Ltd (DRTS)

TIPRANKS
·
Jul 14

Top Executive Makes Bold Move in Alpha Tau Medical’s Latest Insider Trade

TIPRANKS
·
Jul 08

Major Insider Move at Alpha Tau Medical Shakes Up Investor Buzz

TIPRANKS
·
Jul 07

Alpha Tau Medical CFO Raphi Levy Disposes of $232,428 in Common Shares

Reuters
·
Jul 06

Alpha Tau Medical CFO Raphi Levy Disposes of 2,127 Common Shares Worth $27,691.2

Reuters
·
Jul 02

Major Insider Move at Alpha Tau Medical Ltd Shakes Up Investor Watchlists

TIPRANKS
·
Jul 02

Alpha Tau Medical CFO Raphi Levy Reports Open Market Sale of 20,000 Ordinary Shares on June 30 at $12/share - SEC Filing

THOMSON REUTERS
·
Jul 01

Alpha Tau Medical CFO Raphi Levy Sells 20,000 Shares for $240,044

Reuters
·
Jul 01

Major Insider Move at Alpha Tau Medical Shakes Up Investor Buzz

TIPRANKS
·
Jun 27

CFO’s Surprise Stock Move at Alpha Tau Medical Shakes Up Investor Buzz

TIPRANKS
·
Jun 26

Alpha Tau Medical Shareholders Back Board, CEO Dual Role and Auditor at June 2026 AGM

TIPRANKS
·
Jun 26

Alpha Tau Medical Shareholders Approve CEO Sofer to Remain Board Chair

Reuters
·
Jun 26

Alpha Tau Medical CFO Raphi Levy Disposes of 17,500 Common Shares Valued at $167,055.5

Reuters
·
Jun 25

Alpha Tau Medical Continues Its Winning Streak with First-Ever Brain-Cancer Patient Treated Outside the U.S.

TIPRANKS
·
Jun 24

Alpha Tau treats first recurrent glioblastoma patient in Israel with Alpha DaRT under broad-access study

Reuters
·
Jun 23

Wall Street Analysts Are Bullish on Top Healthcare Picks

TIPRANKS
·
Jun 13

Alpha Tau Medical Says FDA Clears Additional Patients, Sites for Alpha DaRT Trial in Glioblastoma

MT Newswires Live
·
Jun 11

Alpha Tau Receives FDA Clearance to Complete Enrollment in Regain Recurrent Glioblastoma Trial and Add Two U.S. Clinical Sites; Early Interim Results Showed 100% Local Disease Control

THOMSON REUTERS
·
Jun 11